{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:15:59Z","timestamp":1784614559360,"version":"3.55.0"},"reference-count":28,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Hosp Pharm"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>The objectives of this case report are to describe the hospitalization of a patient due to a preventable adverse event caused by dulaglutide after restarting therapy following a previous hospitalization where it was held, and to summarize suggested guidance on managing glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) during transitions of care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Summary:<\/jats:title>\n                    <jats:p>A 70-year-old female was admitted with epigastric pain that began a week before admission. One month prior, she was hospitalized for chest pain and diagnosed with a left anterior descending artery occlusion, requiring a 3-vessel CABG. The pharmacy transitions of care service discovered that during her prior stay, she missed 2 doses of dulaglutide and resumed it at the previous dose of 4.5\u2009mg on discharge. After a comprehensive workup, she was diagnosed with gastritis. Her pain improved over the course of 4\u2009days, and she was discharged with instructions to hold the dulaglutide upon discharge and consult her primary care physician for re-titration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This case highlights the need for clearer guidance on the reinitiation of GLP-1 RAs after missed doses while in the hospital. Using available literature, algorithms were generated to provide recommendations when more than 1\u2009weekly GLP-1 RA dose is missed. These algorithms provide guidance for providers during transitions of care and may be studied prospectively to validate their application in a real-world setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/00185787251372054","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T11:02:42Z","timestamp":1758798162000},"page":"33-39","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Missed Doses, Missed Opportunities: Readmission Due to GLP-1RA Interruption Inspires Algorithms to Improve Reinitiation of Therapy at Discharge"],"prefix":"10.1177","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6254-8619","authenticated-orcid":false,"given":"Adrienne","family":"Michelet","sequence":"first","affiliation":[{"name":"Jefferson Health System, Jefferson Einstein, Philadelphia, PA, USA"},{"name":"Temple University School of Pharmacy, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maksudul","family":"Mowla","sequence":"additional","affiliation":[{"name":"Temple University School of Pharmacy, Philadelphia, PA, USA"},{"name":"Christiana Care, Wilmington, DE, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baaba A.","family":"Amo-Brown","sequence":"additional","affiliation":[{"name":"Temple University School of Pharmacy, Philadelphia, PA, USA"},{"name":"Conemaugh Memorial Medical Center, Johnstown, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Temple University School of Pharmacy, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3901-6187","authenticated-orcid":false,"given":"Marissa","family":"Cavaretta","sequence":"additional","affiliation":[{"name":"Temple University School of Pharmacy, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"e_1_3_2_2_2","unstructured":"Collins L Costello RA. Glucagon-like peptide-1 receptor agonists. StatPearls Publishing. Updated February 2024. Accessed October 10 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551568\/"},{"key":"e_1_3_2_3_2","article-title":"A review of current guidelines for the treatment of obesity","volume":"28","author":"Cornier M-A.","year":"2022","unstructured":"Cornier M-A. A review of current guidelines for the treatment of obesity. Am J Manag Care. 2022;28(15 suppl):S288-S296.","journal-title":"Am J Manag Care"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.08.045"},{"key":"e_1_3_2_5_2","article-title":"GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment","volume":"386","author":"Mahase E.","year":"2024","unstructured":"Mahase E. GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment. BMJ. 2024;386:q1645.","journal-title":"BMJ"},{"key":"e_1_3_2_6_2","unstructured":"Latif W Lambrinos KJ Patel P Rodriguez R. Compare and contrast the glucagon-like peptide-1 receptor agonists (GLP1RAs). StatPearls Publishing. Updated February 2024. Accessed October 10 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK572151\/"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00188-2"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010145"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14195"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13603"},{"key":"e_1_3_2_11_2","unstructured":"Naranjo CA Busto U Sellers EM et al Naranjo Adverse Drug Reaction Probability Scale. Evidencio. 2017. Accessed April 4 2025. https:\/\/www.evidencio.com\/models\/show\/661"},{"key":"e_1_3_2_12_2","unstructured":"Victoza (Liraglutide) Package Insert. Novo Nordisk Inc; 2023."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01140-9"},{"key":"e_1_3_2_14_2","unstructured":"Trulicity (Dulaglutide) Package Insert. Eli Lilly and Company; 2023."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0338-3"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2373"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30104-9"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.2337\/cd23-0023"},{"key":"e_1_3_2_19_2","unstructured":"Ozempic (Semaglutide) Package Insert. Novo Nordisk Inc; 2023."},{"key":"e_1_3_2_20_2","unstructured":"BYDUREON BCise (Exenatide ER) Package Insert. AstraZeneca Pharmaceuticals LP; 2023."},{"key":"e_1_3_2_21_2","unstructured":"MOUNJARO (Tirzepatide) Package Insert. Eli Lilly and Company; 2023."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12701"},{"key":"e_1_3_2_24_2","volume-title":"Medications at Transitions and Clinical Handoffs (MATCH) Toolkit for Medication Reconciliation (Prepared by the Island Peer Review Organization, Inc., Under Contract No. HHSA2902009000 13C). AHRQ Publication No. 11(12)-0059","author":"Gleason KM","year":"2011","unstructured":"Gleason KM, Brake H, Agramonte V, Perfetti C. Medications at Transitions and Clinical Handoffs (MATCH) Toolkit for Medication Reconciliation (Prepared by the Island Peer Review Organization, Inc., Under Contract No. HHSA2902009000 13C). AHRQ Publication No. 11(12)-0059. Agency for Healthcare Research and Quality; 2011."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2024.08.033"},{"key":"e_1_3_2_26_2","unstructured":"UpToDate Inc. Metformin. Lexi-drugs. Updated September 12 2025. Accessed August 4 2025. https:\/\/online.lexi.com"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00213-0"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S013"}],"container-title":["Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00185787251372054","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00185787251372054","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00185787251372054","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:41:18Z","timestamp":1777452078000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00185787251372054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1177\/00185787251372054"],"URL":"https:\/\/doi.org\/10.1177\/00185787251372054","relation":{},"ISSN":["0018-5787","1945-1253"],"issn-type":[{"value":"0018-5787","type":"print"},{"value":"1945-1253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]}}}